Here are some testimonials which may help you decide if you would like to subscribe to our resource.
https://www.bridgetodata.org/sites/default/files/2023-03/Testimonials_2023.pdf
The Estonian Cancer Screening Register
National Institute for Health Development
Paldiski mnt 80
Tallinn
ESTONIA
Phone +372 5388 9686
Email: soeluuring@tai.ee
N/A
1. Orumaa M, Innos K, Suurna M, Veerus P. Cervical cancer screening history among women diagnosed with cervical cancer in Estonia 2017-18. Eur J Public Health. 2023 Feb 3;33(1):64-68.
2. Reima H, Soplepmann J, Elme A, Lõhmus M, Tiigi R, Uksov D, Innos K. Changes in the quality of care of colorectal cancer in Estonia: a population-based high-resolution study. BMJ Open. 2020 Oct 8;10(10):e035556. doi: 10.1136/bmjopen-2019-035556.
3. Analysis of selected quality indicators in the Estonian cervical cancer screening program in 2016. Anion, E; Veerus, P. Master thesis. Defended 2018.
4. Vaccarella S, Franceschi S, Zaridze D, Poljak M, Veerus P, Plummer M, Bray F. Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study. Lancet Oncol. 2016 Oct;17(10):1445-1452.
5. Innos K, Valvere V, Padrik P, Eelma E, Kütner R, Lehtsaar J, Tekkel M. Mammography use and mode of detection among breast cancer patients in Estonia. Women Health. 2016;56(2):129-40.
6. Veerus P, Arbyn M, Amati C, Paolo B; EUROCHIP Working Group. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Tumori. 2010 Jul-Aug;96(4):524-8.
In addition to being a unique online reference for population healthcare databases and registries, the B.R.I.D.G.E.
The Norwegian Cardiovascular Disease Registry is a national health register with individually identifiable data that was established to improve the quality of health care for people with cardiovascular disease. The registry was passed into law by the government in March 2010, and data for the register are available starting 2012, with ongoing, annual updates.
Marthe Østrem
Email: hkr.oppdrag@fhi.no
Norwegian Institute of Public Health
Postboks 973 Sentrum
5808 Bergen
NORWAY
Phone number: +47 21 07 70 00
Email: Folkehelseinstituttet@fhi.no
1. Tverdal A, Magnus P. Mortality in Norwegian men and women with an incident myocardial infarction. European Journal of Preventive Cardiology. 2023 Nov;30(16):e72-3.
2. Forster RB, Kjellstadli C, Myklebust TÅ, Egeland G, Sulo G, Bjørge T, Bønaa KH, Juliusson PB, Kvåle R. Treatment and 30-day mortality after myocardial infarction in prostate cancer patients: A population-based study from Norway. Cardiology. 2023 Feb 28;148(1):83-92.
3. Gynnild MN, Hageman SHJ, Dorresteijn JAN, Spigset O, Lydersen S, Wethal T, Saltvedt I, Visseren FLJ, Ellekjær H. Risk Stratification in Patients with Ischemic Stroke and Residual Cardiovascular Risk with Current Secondary Prevention. Clin Epidemiol. 2021 Sep 17;13:813-823.
4. Ildstad F, Ellekjær H, Wethal T, Lydersen S, Fjærtoft H, Indredavik B. ABCD3-I and ABCD2 Scores in a TIA Population with Low Stroke Risk. Stroke Res Treat. 2021 Feb 25;2021:8845898.
5. Johannessen TR, Atar D, Vallersnes OM, Larstorp ACK, Mdala I, Halvorsen S. Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study. BMJ Open. 2021 Feb 24;11(2):e046024.
6. Brustugun OT. Cancer and coronavirus risk. Tidsskr Nor Laegeforen. 2021 Feb 1;141(2).
7. Mohamed Ali A, Wasim D, Løland KH, Rotevatn S, Bleie Ø, Saeed S. Impact of transcatheter aortic valve implantation on left ventricular function recovery, mass regression and outcome in patients with aortic stenosis: protocol of the TAVI-NOR prospective study. BMJ Open. 2021 Jan 20;11(1):e039961.
8. Kvåle R, Bønaa KH, Forster R, Gravningen K, Júlíusson PB, Myklebust TÅ. Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection? Tidsskr Nor Laegeforen. 2020 Dec 29;140(2).
9. Rostami S, Hoff M, Dalen H, Hveem K, Videm V. Genetic risk score associations for myocardial infarction are comparable in persons with and without rheumatoid arthritis: the population-based HUNT study. Scientific Reports. 2020 Nov 24;10(1):1-9.
10. Johannessen TR, Vallersnes OM, Halvorsen S, Larstorp AC, Mdala I, Atar D. Pre-hospital one-hour troponin in a low-prevalence population of acute coronary syndrome: OUT-ACS study. Open Heart. 2020 Jul 1;7(2):e001296.
Its purpose is to collect in one file information on all recorded cases of acute coronary occlusion in Iceland, together with information on risk factors and treatment among persons aged 25-74. It includes selected data on all cases of acute coronary occlusion diagnosed since 1981.
Holtasmári 1, 2. floor
201 Kópavogur
ICELAND
Phone: +354 535-1800
Fax: +354 535-1801
Email: afgreidsla@hjarta.is
Directorate of Health
Katrínartún 2
105 Reykjavík
Kt. 710169-5009
ICELAND
Phone + 354 510 1900
Email 1: mottaka@landlaeknir.is
Email 2: johannag@hjarta.is
1. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennett K, O'Flaherty M, Capewell S. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One. 2010 Nov 12;5(11):e13957.
2. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):761-8.
3. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol. 2003 Nov 1;158(9):844-51.
4. Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir II, Stefansdottir I, Sigvaldason H, Gudnason V. Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate. Scand Cardiovasc J. 2002 Dec;36(6):337-41.
5. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994 Jul;90(1):583-612.
B.R.I.D.G.E. TO DATA® is the most recent and updated version of the RAD-AR (Risk Assessment of Drugs-
The Estonian Drug Treatment Register was established in 2020. All health care providers treating drug dependence are required to send notification to the Register when starting or finishing a treatment episode. Each record contains personal identifiers (name and unique ID-code assigned to all residents of Estonia), socio-demographic characteristics, drugs used, date and code of diagnosis (ICD-10), as well as data on treatment episode.
